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Abstract
Systemic administration of the noncompetitive NMDA-receptor antagonist, MK-801, has been proposed to model cognitive
deficits similar to those seen in patients with schizophrenia. The present work investigated the ability of a dopamine-
binding DNA aptamer to regulate these MK-801-induced cognitive deficits when injected into the nucleus accumbens. Rats
were trained to bar press for chocolate pellet rewards then randomly assigned to receive an intra-accumbens injection of a
DNA aptamer (200 nM; n=7), tris buffer (n=6) or a randomized DNA oligonucleotide (n=7). Animals were then treated
systemically with MK-801 (0.1 mg/kg) and tested for their ability to extinguish their bar pressing response. Two control
groups were also included that did not receive MK-801. Data revealed that injection of Tris buffer or the random
oligonucleotide sequence into the nucleus accumbens prior to treatment with MK-801 did not reduce the MK-801-induced
extinction deficit. Animals continued to press at a high rate over the entire course of the extinction session. Injection of the
dopamine aptamer reversed this MK-801-induced elevation in lever pressing to levels as seen in rats not treated with MK-
801. Tests for activity showed that the aptamer did not impair locomotor activity. Results demonstrate the in vivo utility of
DNA aptamers as tools to investigate neurobiological processes in preclinical animal models of mental health disease.
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Introduction
In general, schizophrenia ischaracterized by positive, negative and
cognitivesymptoms. Cognitivedeficitsappear in the realmofworking
memory, executive function, attention and processing speed [1]. One
aspect of executive function concerns updating, or monitoring,
information in one’s working memory, which has been considered in
terms of coding incoming information and replacing what is no
longer relevant [2]. The concept of inhibition contributes to this
aspect of executive function where there is a requirement to
intentionally overrule a propensity to make an automatic, predom-
inant response. At the heart of this is the ability of an organism to
switch behavioral output in response to a change in environmental
contingencies [3]. Individuals with schizophrenia are said to
‘perseverate’, showing difficulty in inhibiting behavioral tendencies
on a previously learned taskeven when it is inappropriate to do so[4].
NMDA receptor antagonists, such as MK-801, have been used
in rodents to model cognitive dysfunction as would be observed in
individuals with schizophrenia [5–6]. In one behavioral model
using MK-801, rats are trained to press a lever to receive a
chocolate pellet reward. After 5 days of training, rats are subjected
to one extinction test, whereby lever pressing no longer results in
presentation of a chocolate pellet reward. In normal rodents,
during the extinction test, the lever pressing response starts high
but quickly decreases (extinguishes) showing that the rats are able
to inhibit their behavioral tendency to press the lever. Work has
shown that a moderate dose (0.05–0.1 mg/kg) of MK-801
produces a persistent, elevated lever pressing response during the
extinction test [7–8] modeling an executive function deficit
(perseveration). In the Holahan, et al., study, D1- or D2-like
receptor antagonists reversed the MK-801-induced behavioral
profile and the nucleus accumbens showed elevated neural activity
in the MK-801-treated group compared to saline controls (8).
These data were interpreted to suggest that MK-801 induced
cognitive deficits similar to perseveration, which may be in part
due to overactivity of dopamine in the nucleus accumbens.
The purpose of the present study was to inject a DNA aptamer
with binding affinity for dopamine into the nucleus accumbens and
determine its effect on the MK-801-induced deficit in extinction
responding. Aptamers are single stranded DNA or RNA sequences
that fold into distinct conformations capable of binding to a target
molecule [9]. As molecular recognition probes, aptamers have
binding affinities and specificities that are comparable to, and in
some cases even surpass, those of monoclonal antibodies. In certain
applications, aptamer technology can offer several advantages over
antibodies [10]. High-purity aptamers can be chemically synthe-
sized at a low cost with no batch-to-batch variability. Aptamers are
more chemically stable than antibodies under most conditions, have
a longer shelf life, and show little to no immunogenicity.
Furthermore, the process for their selection, known as SELEX, is
an in vitro screening process, which allows for a greater degree of
control over the ultimate selectivity and affinity of the final product
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a viable alternative to antibodies in many analytical, diagnostic and
therapeutic applications.
Despite their exciting potential, the research surrounding the
application of aptamers in the central nervous system is extremely
limited [13]. Aptamers have been selected that target B1-CT, the
short cytoplasmic tail of the BACE1 protein and bA4, an amyloid
peptide, both of which may provide diagnostic or therapeutic tools
for Alzheimer’s disease [14]. A group ofaptamers that competitively
binds to Nogo-66 receptor in vitro has shown promise in promoting
axonal elongation [15]. A DNA aptamer has also been developed to
detect Neuropeptide Y, a central nervous system peptide implicated
in feeding behaviors [16]. RNA aptamers have been selected that
displace cocaine from the nicotinic acetylcholine receptor in cell
culture [17]–[18]. Recently, an aptamer-gold nanorod assay was
developedtodetectadenosinephosphatesinsamples extractedfrom
the brains of Sprague-Dawley rats [19].
An RNA aptamer for dopamine with a moderate binding
affinity was reported in the late 1990s [20]. More recently, the
DNA homolog of this RNA aptamer (see Figure 1 for the
sequence) was found to target dopamine with improved binding
and stability, and could also bind norepinephrine with a similar
affinity [21]. To date, neither the RNA nor DNA dopamine
aptamer has been investigated in vivo, nor has an aptamer for any
target ever been tested directly in the brain.
The primary goal of this work was to investigate whether this
DNA dopamine aptamer would retain its binding properties in
vivo, by injecting it into the nucleus accumbens (Acb) of the rat
brain. We hypothesized that the aptamer would work in a similar
fashion as an antagonist but, rather than binding to the receptor,
bind directly to both dopamine (and norepinephrine) molecules,
thus stopping their action on the receptor. In this study, we report
on the behavioral effects of aptamer injection into the nucleus
accumbens of MK-801-treated rats compared to rats treated with
buffer or a random DNA oligonucleotide. Our results suggest that
aptamer treatment was selective in mitigating the behavioral
effects of peripheral MK-801 administration.
Results
Operant Task: intra-accumbens aptamer ameliorates
MK-801-induced perseveration
Acquisition. Rats were trained drug-free over 5 days to press
a lever to receive a chocolate pellet reward. A two-way ANOVA
(day by group) on the mean number of correct presses per day
revealed a main effect of day (F(4,16)=94.44, p,0.001) with no
group differences (F(4,26)=1.57) and no interaction
(F(16,104)=1.27). This suggests that all groups learned the task
similarly over the 5-day acquisition period which was to be
expected as no experimental manipulations were carried out
during this time.
Extinction. Forty-eight hours after the last rewarded
acquisition day, rats were treated with intra-accumbens injection
(0.5 ml per hemisphere for all intra-accumbens injections) of tris
buffer and systemic MK-801 (0 nM/ MK, n=7; all MK-801
doses=0.1 mg/kg/ml), intra-accumbens injection of 200 nM
aptamer and systemic MK-801 (200 nM/ MK, n=7), intra-
accumbens injection of the random oligonucleotide sequence and
systemic MK-801 (Random/ MK, n=7), intra-accumbens
injection of tris buffer and systemic saline (0 nM/ Saline, n=5),
or intra-accumbens injection of 200 nM aptamer and systemic
saline (200 nM/ MK, n=5). Fifteen minutes after the systemic
injection, rats were placed into the operant chambers and given a
30 min extinction session where lever presses did not produce any
chocolate pellet reward. Supplemental Videos S1 and S2 show a
30-sec sample of bar pressing behavior from a rat injected with
vehicle into the nucleus accumbens and MK-801 systemically
(Video S1) and a rat injected with aptamer into the nucleus
accumbens and MK-801 systemically (Video S2). The vehicle
animal is shown to press incessantly in the absence of reward on
the correct lever while the aptamer animal presses a few times then
stops when no reward delivery occurs. Both video clips showing
pressing behavior at approximately the 20 min mark of the 30 min
extinction test.
The extinction data for correct lever presses are shown in
Figure 2A. Cumulative correct presses during the extinction test
were analyzed with a two-way, repeated-measures ANOVA
(group by 5-min time interval). Analysis revealed main effects of
group (F(4,26)=3.84, p,0.05) and interval (F(5,20)=56.74,
p,0.001) and a significant interaction between interval and group
(F(20,130)=6.47, p,0.001). Fisher’s Least Significant Difference
(LSD) post-hoc comparisons revealed differences between the
200 nM/ MK group and the 0 nM/ MK and Random/ MK
groups (p,0.05). The 200 nM/ MK group did not differ from the
200 nM/ Saline or 0 nM/ Saline groups.
Cumulative incorrect lever presses over the 30-min extinction
session for each of the groups are shown in Figure 2B. A two-way
ANOVA (group by 5-min time interval; Fig 1B) revealed no
significant effects.
Immediately after the extinction test, 3 animals that were
injected with 200 nM aptamer into the nucleus accumbens and
MK-801 systemically and 3 animals that were injected with vehicle
into the nucleus accumbens and MK-801 systemically were
euthanized for immunohistochemistry (results below).
Locomotor Activity: intra-accumbens aptamer does not
impair locomotion
One week after the extinction test, the remaining animals were
randomly re-assigned and given a second intra-accumbens
injection and subjected to a 30-min locomotor test in a different
apparatus. Data collected included distance traveled (in meters;
Fig. 3A), speed (in meters/ sec; Fig. 3B) and arm entries (Fig. 3C).
Data from 1 animal in the 200 nM/ Saline group were lost.
Separate one-way ANOVAs were run on each of the dependent
measures. For each measure, there were no main effects of group
(Distance: F(4,19)=1.53; Speed: F(4,19)=1.53; Arm Entries:
F(4,19)=2.31).
Figure 1. Aptamer sequence. Schematic of the aptamer sequence
used in this experiment (top). The two complementary regions shown
in red and the conserved bases shown in blue are thought to form the
target binding site. Also shown is the sequence of the random
oligonucleotide control (bottom).
doi:10.1371/journal.pone.0022239.g001
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aptamer injection reduces immunohistochemical
staining of phosphorylated tyrosine hydroxylase
Fifteen minutes after the extinction test, 3 animals injected with
200 nM aptamer and 3 injected with vehicle into the nucleus
accumbens (all injected systemically with MK-801) were eutha-
nized and brains were removed for immunohistochemical analysis
of tyrosine hydroxylase (TH) and phosphorylated TH (pTH) in the
nucleus accumbens (Figure 4). The ratio of pTH: TH accumbens
staining (Fig. 4A) was reduced in the 200 nM-injected group
compared to the vehicle-injected group (t(4)=7.02, p,0.01). This
was not due to differences in TH staining (Fig. 4B; t(4)=1.70) but
rather due to reductions in pTH staining in the 200 nM group
(Fig. 4C; t(4)=9.25, p,0.01). Representative sections (Fig. 4D and
E) from both groups show that the reduced pTH staining was
localized to the nucleus accumbens shell region in the 200 nM-
injected group.
Discussion
A behavioural procedure to potentially model cognitive deficits
associated with schizophrenia concerns the use of MK-801
during extinction of a learned response. A moderate dose (0.05–
0.1 mg/kg) of MK-801 has been shown to produce a persistent,
elevated lever pressing response throughout an entire 30 min
extinction session [8]. MK-801 has been reported to increase
dopamine output in the striatum [22] and frontal cortex [23]
likely by increasing firing rates of mesolimbic dopaminergic
neurons [24–25]. Consistent with this, animals pretreated with
Figure 2. Intra-accumbens aptamer injection reverses the MK-801-induced elevation in extinction pressing. A) Cumulative correct
lever responses per 5-min interval over the 30-min extinction session. B) Cumulative number of incorrect lever presses per 5-min interval over the 30-
min extinction session. Groups pretreated with intra-accumbens vehicle (0 nM/ MK; n=7) or the random oligonucleotide sequence (Random/ MK;
n=7) and systemically with 0.1 mg/ kg MK-801 showed elevated correct lever pressing throughout the entire 30-min extinction session compared to
animals pretreated with 200 nM dose of the aptamer (200 nM/ MK; n=7) and both groups treated systemically with saline (0 nM/ saline; n=5 and
200 nM/ saline; n=5). Correct extinction pressing was not significantly different between the 200 nM/ MK group and the 0 nM/ saline or the 200 nM/
saline groups. *, p,0.05; numbers in parentheses=animals per group. No significant differences were detected when measuring incorrect lever
presses during the extinction session. Data expressed as mean 6 SEM.
doi:10.1371/journal.pone.0022239.g002
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antagonists showed normalized extinction responding under
MK-801 [8].
These findings can best be put into the context of a model
concerning neural mechanisms underlying schizophrenia as
developed by Carlsson and colleagues (see for example [26–27].
In this model, cortical regulation of dopamine output is mediated
by two pathways: the ‘‘accelerator’’ and the ‘‘brake’’. The brake
pathway consists of combined glutamate and GABA synapses.
Blockade of the glutamate portion of this pathway (for example,
with MK-801) reduces GABA inhibitory control of midbrain
dopaminergic neurons causing elevated dopamine output at
terminal projection sites (e.g., nucleus accumbens, cortex). The
work of Holahan et al., showed that MK-801 administration was
associated with reduced neural activation in the infralimbic cortex
and elevated extinction pressing that was blocked by dopamine
receptor antagonists [8]. Therefore, MK-801 may increase rates of
midbrain dopamine neural activity by reducing cortical glutama-
terigic control leading to enhanced dopamine-dependent behav-
iors such as perseveration.
An alternative interpretation for the behavioral effect of MK-
801 is that it altered a more fundamental motivational state
enhancing the conditioned reinforcing properties of the condi-
tioned cues. Indeed, MK-801 has been shown to prolong
progressive ratio responding compared to saline-injected controls
[8] and MK-801 potentiates both food unconditioned [28–29] and
conditioned [30] behavioral responses. This could occur for a
number of reasons including elevations in dopamine efflux in the
Acb [8,31,32], a deficit in signaling processes that participate in
termination of eating-satiety signals [29], or, as hypothesized in the
present report, induction of a non-specific preservative effect on
ongoing behavior. In any case, the behavioral changes observed
can be ascribed to elevations in dopamine output in the Acb; the
target of the aptamer injections.
In the current report, rats treated with 0.1 mg/ kg MK-801
systemically and either tris-buffer vehicle (0 nM group) or the
random oligonucleotide sequence into the nucleus accumbens
showed higher rates of lever pressing during extinction than rats
treated systemically with saline (0 nM or 200 nM aptamer into the
accumbens). The MK-801- injected group pre-treated with a
200 nM dose of the aptamer into the nucleus accumbens pressed
significantly less than the MK-801 groups that received vehicle
(0 nM) or the random oligonucleotide sequence pre-treatment in
the nucleus accumbens. Furthermore, there were no significant
difference in extinction pressing between groups that received
central 0 nM or 200 nM aptamer pre-treatment and saline, rather
than MK-801, peripheral administration. This, in conjunction with
the finding that the 200 nM dose of aptamer did not affect incorrect
lever pressing or locomotor activity, suggests that aptamer pre-
treatment was selective in reversing, or at least minimizing, the
cognitive-behavioral deficits of peripheral MK-801 administration.
The cross maze used to test locomotion was not one with open
and closed arms as would be used to test anxiety but rather, one
with all closed arms minimizing anxiety-eliciting effects. With the
cross maze, both automated measures and manual measurements
of arm entries were obtained. For all measures of locomotion, no
differences were detected between MK-801-injected groups with
either 0 nM, 200 nM or random aptamer injections. Horizontal
activity in MK-801-injected animals is robustly elevated [8,33–35]
independent from the apparatus used. As there was no difference
in activity between the groups injected with MK-801, it is
concluded that the effects on extinction cannot be ascribed to a
general lack of activity. While the 200 nM group injected with
saline did show some reductions in the number of arm entries, this
was not significantly different from the 0 nM/ saline group.
Therefore, it would be premature to conclude that the aptamer by
itself reduces locomotor activity.
Figure 3. Horizontal activity was not affected by intra-
accumbens injection of the aptamer. Locomotor activity was
assessed in an elevated cross maze for 30 min. Activity was measured as
total distance in meters traveled (A), average speed in meters/ sec (B)
and total arm entries (C). No main effect of group was detected. Arm
entries in all MK-801-injected groups (0 nM/ MK, 200 nM/ MK and
Random/ MK; n=5 per group) were significantly different from the
200 nM/ saline-treated group (n=5) (*, p,0.05). The saline treated
groups were not significantly different on any measure of activity. Data
are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0022239.g003
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and phosphorylated TH (pTH) in the nucleus accumbens showed
reduced levels of pTH in the aptamer-injected animals compared
to vehicle (both treated with MK-801). The synthesis and secretion
of dopamine is critically dependent on TH activation through
phosphorylation taking place at serine residues (Ser) 8, 19, 31 and
40 [36]. There is strong evidence that phosphorylation of tyrosine
hydroxylase at Ser40 leads to TH activation and catecholamine
(CA) synthesis in vivo and likely serves as a choke-point for
dopamine and norepinephrine synthesis [36]. The observation
that there was less immuno detection of phospho Ser40 TH
suggests that not only does the aptamer bind to and render
dopamine/norepinephrine dysfunctional but it may also limit the
subsequent synthesis of dopamine/ norepinephrine. In this case,
reduced pTH staining in the aptamer group would be indicative of
a reduction in dopamine synthesis.
The reduction in pTH in the aptamer group might be due to
low concentrations of free extracellular dopamine (i.e., not bound
by the aptamer) working on presynaptic autoreceptors [37].
Consistent with this hypothesis, low concentrations of dopamine
(DA) agonists, such as apomorphine (Apo), inhibit TH activity in
striatal slices and synaptosomal preparations (reviewed by [37].
Initially, the aptamer would bind to dopamine/ norepinephrine
that has been released into the synaptic cleft. When the aptamer is
bound, it would reduce the effect of the neurotransmitter on the
postsynaptic receptors. This is the primary/ direct effect of the
aptamer that would happen immediately and for some unknown
time. Binding of the aptamer to the target also has a secondary
effect; in this case, reducing pTH and ultimately, CA synthesis.
Therefore, the behavioral results are consistent with the primary/
direct effects of the aptamer and the secondary/ indirect effects of
the aptamer (reduction in pTH). It should be noted that TH
staining was similar between groups suggesting the aptamer did
not damage dopaminergic terminals.
Results indicate that 200 nM aptamer pre-treatment was
successful in instating extinction in hypoglutamatergic/hyperdo-
paminergic animals. If the failure of achieving extinction in MK-
801-treated animals is partly caused by an overactivation of the
mesolimbic dopaminergic system, the aptamer was successful in
binding to dopamine within the nucleus accumbens, rendering it
dysfunctional, resulting in a ‘‘normal’’ extinction process.
The strength of aptamer-target binding, which is the result of a
combination of hydrogen bonding, electrostatic interactions, van
der Waals forces and stacking interactions [38], is determined by
the dissociation constant (Kd). The judicious choice of an aptamer
based on its binding affinity could allow for significant target
binding, and therefore noticeable effects, only when dopamine
concentrations are well above basal levels. The aptamer used in
this study has Kd values in the hundreds of nanomolar for both
dopamine and norepinephrine. As the basal dopamine level in the
nucleus accumbens can be estimated to be 50 to 70 times less than
this Kd [39], aptamer-target binding can be predicted to be very
low. This may explain why no behavioural differences were noted
in non-MK-801-treated rats. In MK-801-treated rats, dopamine
concentrations in the Acb have been shown to increase by 135–
145% [40]. Similar increases in dopamine output in the nucleus
accumbens have also been reported during the presentation of
cues which were previously paired with a food reward [41]. As
comparable increases in dopamine are thought to be occurring in
our extinction experiment, dopamine concentration, although still
appreciably below the Kd of the aptamer, may perhaps be high
enough to elicit more noticeable effects. Relative concentration
arguments may also shed some light on the interaction of
norepinephrine with this aptamer. Although this aptamer also
Figure 4. Representative histological sections from nucleus accumbens show reduced pTH staining in aptamer-treated rats. A)
Quantification of the phosphorylated tyrosine hydroxylase (pTH) to tyrosine hydroxylase (TH) ratio in the nucleus accumbens shell region (AcbShell)
shows a lower ratio in the 200 nM/ MK group (** p,0.01). B) Quantification of TH staining in the AcbShell shows similar levels between the 0 nM/ MK
group and 200 nM/ MK group. C) Quantification of pTH staining in the AcbShell shows lower levels of staining in the 200 nM/ MK group compared to
the 0 nM/ MK group (** p,0.01). n=3/ group. Abbreviations: ACA, anterior commisure; AcbCore, nucleus accumbens core; AcbShell, nucleus
accumbens shell. Scale bars=500 mm. Magnifications shown at top of 0 nM images. Data expressed as mean 6 SEM.
doi:10.1371/journal.pone.0022239.g004
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abnormal concentrations of norepinephrine in the nucleus
accumbens are about an order of magnitude lower than the
respective dopamine levels [40]. As a result, aptamer-norepineph-
rine complexes would be predicted to be considerably less
abundant. Although this does not completely rule out a role for
norepinephrine sequestration in these behavioral effects, it does
suggest that, within this region of the brain at least, dopamine
binding is more likely the cause.
Results of the current study provide several promising starting
points for further exploration of aptamer technology in the central
nervous system. First and foremost, finding that the aptamer, when
injected into the nucleus accumbens, does not have overtly
devastating consequences on behavioural output is a major step.
Second, the near-selective effect on reversing cognitive deficits
without drastic motoric impairment lends exceptional support for
the use of DNA aptamers in the further study of preclinical animal
models of mental health disease. A clear impediment to the use of
aptamers in the brain will be their efficient and targeted delivery
into the brain. Aptamer blood-brain-barrier (BBB) bypass is
necessary in order to investigate the compound’s pharmacokine-
tical properties and consider it a feasible therapeutic agent. Future
work will examine strategies for delivery of these aptamers across
the BBB, such as the use of immunoliposomes, and will investigate
the pharmacokinetics of this aptamer in vivo.
Materials and Methods
Ethics Statement
All animal procedures were in accordance with Canadian
Council on Animal Care (CCAC) guidelines, the NIH Guide for
the Use and Care of Laboratory Animals and approved by the
Carleton University Animal Care Committee (AUP ID P09-16).
Subjects
Male Long Evans rats (n=31) were purchased from Charles
River, St. Constant, Quebec, Canada and housed in groups of two
in polycarbonate 48626620 cm cages prior to surgery and
individually housed post surgery. The vivarium was temperature
(21uC) and lighting (12-hour light/dark cycle; lights on at 0800)
controlled. Rats were handled for five minutes each day for seven
days, to minimize stress. Approximately ten days following the
intracranial surgical procedure, rats were placed on a food
restriction schedule for approximately 8 days, until each animal
reached a target of 85% of its initial weight (250–300 g).
Surgical procedure
Standard stereotactic rodent surgical procedures were used.
Animals were anaesthetized with isofluorane and two stainless steel
12 mm guide cannula (25 Ga) were implanted bilaterally,
targeting the nucleus accumbens (Acb) at the following coordinates
relative to bregma: antero-posterior (AP)=21.7, latero-medial
(LM)=+/21.5 and dorso-ventral (DV)=26.0. Cannula were
secured in place using dental cement. Obturators (32 Ga) were
inserted in each cannula. A subcutaneous dose (0.2 ml) of the
analgesic Metacam was administered immediately after surgery
and again 12 and 24 h later.
Drugs
The noncompetitive NMDA receptor antagonist, MK-801
(Sigma-Aldrich), was stored frozen as a stock solution of 1.0 mg/
ml in 0.9% sterile saline. It was thawed and diluted to the working
concentration (0.10 mg/ kg; pH=7.4) with 0.9% sterile saline on
the day it was to be used. The dose was based on previous reports
[7,42–44].
The DNA aptamer [21], as well as the random oligonucleotide
used in this work, were prepared by standard phosphoramidite
chemistry on a Bioautomation MerMade DNA synthesizer (see
Figure 1 for the sequences). The sequences were purified by
polyacrylamide gel electrophoresis and the masses were confirmed
by ESI-MS.
Operant Conditioning Procedure
Acquisition. Six operant conditioning chambers (Coulbourn
Instruments; 30.5 cm W625.5 cm D630.5 cm H) housed in
insulated casings were used. Upon pressing the left lever two times
(FR2), the house light went off, the panel lights above the lever
changed from red to green and the pellet dispenser released one
45-mg chocolate pellet (BioServe, New Jersey) into the hopper.
Presses on the left lever were correct and presses on the right lever,
incorrect. During the five-day acquisition phase, rats were placed
into the chambers for 30 minutes each day. Cumulative lever
presses were recorded.
Extinction. The extinction session was 30 min and occurred
on the third day after the last reinforced acquisition day. No food
reward was delivered in response to correct lever pressing but the
houselight went off and the panel lights changed from red to green.
Cumulative lever presses were recorded.
Locomotor testing
A subset of rats (n=25) were tested for locomotor activity 1
week after the extinction test. The apparatus was an elevated
(75 cm), closed wooden cross maze (6069 cm arms). Each animal
was placed into the center of the maze for a 30 min test.
Horizontal activity (distance traveled, speed and arm entries) was
recorded using the HVS Image 2100 Plus tracking system (HVS
Image Ltd, UK).
Central administration
Obturators were removed and two stainless-steel injection
cannula (13 mm, 32 Ga) connected to two 10 ml Hamilton
syringes by polyethylene tubing were inserted into the guide
cannula. Syringes were connected to an injection pump (Braintree
Scientific, Inc.), programmed to deliver a 0.5 ml injection at a rate
of 0.25 ml/min. The injection cannula were left in place for an
additional 60 s. During microinjections, each animal was allowed
to move freely in its home cage.
Peripheral administration
Each animal was administered a subcutaneous injection of MK-
801 (0.1 mg/ kg in a volume of 0.3 ml) or saline immediately after
the accumbens injection.
The following groups were used: intra-accumbens injection of tris
buffer and systemic MK-801 (0 nM/ MK, n=7); intra-accumbens
injectionof200 nMaptamerandsystemicMK-801(200 nM/MK,
n=7); intra-accumbens injection of the random oligonucleotide
sequence and systemic MK-801 (Random/ MK, n=7); intra-
accumbens injection of tris buffer and systemic saline (0 nM/
Saline, n=5); intra-accumbens injection of 200 nM aptamer and
systemic saline (200 nM/ MK, n=5). All animals were run through
the operant acquisition and extinction procedure and a subset
(n=5/ group) were tested for locomotor activity.
Histology
To investigate the in vivo effects of aptamer injection into the
nucleus accumbens, 3 animals injected with 200 nM aptamer and
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with tris buffer and an s.c. injection of MK-801 were euthanized
immediately after the extinction test. Brains were immersion fixed
in a 4% paraformaldehyde/ 0.01 M phosphate buffer solution
(PB; pH 7.4) and used for immunohistochemistry using methods
as described [45]. Incubation in the primary antibodies (1:1000
mouse anti-tyrosine hydroxylase from Immunostar or 1:500 rabbit
anti-phosphorylated tyrosine hydroxylase (S40) from Abcam)
occurred overnight at room temperature. Incubation in the
secondary antibodies (1:500 goat anti-rabbit 594 or 1:500 goat
anti-mouse 488; Molecular Probes) occurred for 2 h at room
temperature. Sections were mounted on glass slides and cover-
slipped using Fluormount (Sigma). Alternate sections were stained
with cresyl violet to verify cannula placements.
Immunohistochemical Quantification
Using an Olympus BX61 microscope (Olympus Canada, ON),
digital images of the nucleus accumbens core and shell regions
were obtained (206, NA 0.4; InVitro version 3.2.2; Media
Cybernetics, MD) using the same exposure time to reduce
photobleaching and equalize intensities across subjects. Pixel
intensity maps were generated for both TH and pTH staining
using the Image-Pro Analyzer version 6.2.1.491 (Media Cyber-
netics, MD). Briefly, 5 horizontal lines were generated across the
entire nucleus accumbens region and intensity measures were
collected beginning at the anterior commisure followed by the core
and finally the shell. An average raw pixel intensity profile was
generated for each section. For quantification, intensity measures
obtained in the shell were normalized to intensity measures in the
anterior commisure (core staining was negligible at the exposure
times used). Statistical analyses (t-tests) between groups were made
using these normalized intensities on TH intensity, pTH intensity
and the ratio of pTH:TH to account for any variation in staining
or image processing.
Supporting Information
Video S1 This rat was given an intra-accumbens injection of
200 nM dose of the dopamine-binding aptamer and 5 min later,
given a systemic injection of MK-801 prior to the extinction
session. The video shows a 30 sec clip of bar pressing behavior
approximately 20 min after the start of the extinction session.
(WMV)
Video S2 This rat was given an intra-accumbens injection of
vehicle (Tris buffer; 0 nM) and 5 min later, given a systemic
injection of MK-801 prior to the extinction session. The video
shows a 30 sec clip of bar pressing behavior approximately 20 min
after the start of the extinction session.
(WMV)
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